Abstract: A separator device (100) includes a separation chamber (107) defined at its lower end by a fluidization fluid panel (111). The separation chamber (107) receives incoming slurry (113) via a slurry inlet (102). The separator device may be characterized in that means (122) for supplying pre-sheared aerated fluidization fluid is provided above the fluidization fluid panel (111). The means (122) for supplying pre-sheared aerated fluidization fluid includes a novel sparger (119) comprising a flexible perforated membrane which is configured to supplementally shear the pre-sheared aerated fluidization fluid and uniformly distribute microbubbles (129) throughout the separation chamber (107).

Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.

Abstract: A feedwell assembly (1) having a feedwell (3) and feed dilution apparatus (27) is characterised in that the feed dilution apparatus (27) includes a centrifugal impeller (16) arranged within a pump housing (9). The pump housing is arranged below a weir box (12) having an upper opening and a spill lip (12b). The spill lip (12b) is arranged at an upper periphery of the weir box (12). The spill lip (12b) is configured to be arranged below an air-liquid interface (20) during operation such that there is a depth of submergence (26) between the spill lip (12b) and the air-liquid interface (20).

Abstract: A stable liquid pharmaceutical preparation of an anti-influenza virus antibody and, more specifically, a stable liquid pharmaceutical preparation that comprises: (A) an anti-influenza virus antibody or a mixture of two or more different types of anti-influenza virus antibodies; (B) a surfactant; (C) a sugar or a sugar derivative; and (D) an amino acid. The stable liquid pharmaceutical preparation for an anti-influenza virus antibody disclosed herein has excellent storage stability at low temperature (5° C.), room temperature (25° C.), and high temperature (40° C.) and excellent long-term (12 months) storage stability, and may be administered intravenously, intramuscularly, transdermally, subcutaneously, intraperitoneally, topically, or in combinations thereof.

Abstract: The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.

Abstract: The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.

Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.

Abstract: The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.

Abstract: A feedwell assembly (1) having a feedwell (3) and feed dilution apparatus (27) is characterised in that the feed dilution apparatus (27) includes a centrifugal impeller (16) arranged within a pump housing (9). The pump housing is arranged below a weir box (12) having an upper opening and a spill lip (12b). The spill lip (12b) is arranged at an upper periphery of the weir box (12). The spill lip (12b) is configured to be arranged below an air-liquid interface (20) during operation such that there is a depth of submergence (26) between the spill lip (12b) and the air-liquid interface (20).

Abstract: A solenoid valve having an explosion-proof structure, a fuel feeding system, and a method of manufacturing the solenoid valve having an explosion-proof structure are provided. The solenoid valve having an explosion-proof structure includes: a body including a channel through which a fluid flows; a housing connected to the body and having one surface opened; a solenoid assembly arranged inside the housing and electrically connected to a controller; an armature, at least a portion of which is arranged in the channel and which opens or closes the channel by moving relative to the solenoid assembly by a magnetic field generated by the solenoid assembly; and a cover plate arranged on the one surface of the housing to face the armature.

Abstract: A stable liquid pharmaceutical formulation according to the present invention includes an antibody or antigen-binding fragment thereof, a surfactant, a sugar or a sugar derivative, a buffer, and a stabilizer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity not only when antibody content is low but also when antibody content is high, and exhibits superior long-term storage stability based on superior stability observed under accelerated conditions and harsh conditions.

Abstract: A solenoid valve having an explosion-proof structure, a fuel feeding system, and a method of manufacturing the solenoid valve having an explosion-proof structure are provided. The solenoid valve having an explosion-proof structure includes: a body including a channel through which a fluid flows; a housing connected to the body and having one surface opened; a solenoid assembly arranged inside the housing and electrically connected to a controller; an armature, at least a portion of which is arranged in the channel and which opens or closes the channel by moving relative to the solenoid assembly by a magnetic field generated by the solenoid assembly; and a cover plate arranged on the one surface of the housing to face the armature.

Abstract: Disclosed is a stable pharmaceutical formulation, comprising a fusion protein in which the extracellular ligand-binding domain of a human p75 tumor necrosis factor receptor is fused to the Fc domain of human IgG and a succinate buffering agent, without comprising a stabilizer. The stable pharmaceutical formulation enables the long-term storage of the TNFR-Fc fusion protein formulation and can exhibit superior storage stability without the need for demanding storage conditions, and is a simple formulation because no stabilizer is comprised therein and is thus more economical than other stabilizer-comprising formulations.

Abstract: A stable liquid pharmaceutical preparation of an anti-influenza virus antibody and, more specifically, a stable liquid pharmaceutical preparation that comprises: (A) an anti-influenza virus antibody or a mixture of two or more different types of anti-influenza virus antibodies; (B) a surfactant; (C) a sugar or a sugar derivative; and (D) an amino acid. The stable liquid pharmaceutical preparation for an anti-influenza virus antibody disclosed herein has excellent storage stability at low temperature (5° C.), room temperature (25° C.), and high temperature (40° C.) and excellent long-term (12 months) storage stability, and may be administered intravenously, intramuscularly, transdermally, subcutaneously, intraperitoneally, topically, or in combinations thereof.

Abstract: A stable liquid pharmaceutical formulation according to the present invention includes an antibody or antigen-binding fragment thereof, a surfactant, a sugar or a sugar derivative, a buffer, and a stabilizer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity not only when antibody content is low but also when antibody content is high, and exhibits superior long-term storage stability based on superior stability observed under accelerated conditions and harsh conditions.

Abstract: Provided is a method of providing an unmanned dialogue service according to an embodiment of the inventive concept. The method includes transmitting or receiving text message data constituting a dialogue to or from a user terminal in an unmanned dialogue model, analyzing the dialogue to determine whether a counselor switching situation has occurred, transmitting a dialogue handover request including information regarding the dialogue to a counselor management apparatus when it is determined that the counselor switching situation has occurred, and automatically switching into a mode for relaying transmission or reception of messages between the user terminal and a counselor terminal that receives a task for processing the dialogue handover request allocated by the counselor management apparatus.

Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.

Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.

Abstract: The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.

Abstract: Provided is a method of providing an unmanned dialogue service according to an embodiment of the inventive concept. The method includes transmitting or receiving text message data constituting a dialogue to or from a user terminal, analyzing the dialogue and determining whether an abnormal situation has occurred, transmitting an assistance request including information regarding the dialogue to a human agent management apparatus when it is determined that the abnormal situation has occurred, receiving dialogue advancement guide information, which is a response to the assistance request, from the human agent management apparatus, wherein the dialogue advancement guide information is configured using input data of a human agent input to a human agent terminal connected to the human agent management apparatus and configured to receive a task for processing the assistance request allocated by the human agent management apparatus, and continuing the dialogue using the dialogue advancement guide information.